PRESS RELEASE

For Immediate Release

Better understanding, better outcomes Alzheimer’s media educational programme

Alzheimers Educational Programme

 

Kuala Lumpur, September 20, 2022 — To honour the annual World Alzheimer’s Day that falls on the 21st of September, Roche hosted a virtual educational event for the media which featured leading experts in diagnostics, early Alzheimer’s disease (AD), and clinical research. The desired outcome envisioned for this media education is for the media to understand the development space in Alzheimer’s disease and to be able to accurately report on upcoming clinical trial read-outs, while gaining good understanding on the unmet need in Alzheimer’s disease and the ideal future-state of diagnosis and treatment for this disease.

Featured during the panel session were Dr Rachelle Doody, Global Head of Neurodegeneration at Roche; Professor Bruno Vellas, Chief of the Alzheimer's Disease Clinical and Research Center at the University Hospital Center in Toulouse, France; Dr Geoffrey Kerchner, Global Head of Early Development in Neuroscience & Rare Diseases, pRED, Roche; and Dr Bruce Jordan, from Personalized Healthcare Solutions of Roche Diagnostics.

The session started off with the topic on understanding Alzheimer’s disease and its potential treatment targets while simultaneously providing an overview of what Alzheimer’s disease is, it’s prevalence and the relationship to dementia and how it impacts the brain. Dr Geoffrey Kerchner, also provided explanation of the AD continuum and the importance of targeting early AD – iceberg analogy and also explained on the beta-amyloid and tau as key therapeutic targets.

As early symptoms of AD, including short-term memory loss and minor physical impairment, are often dismissed as an ageing process, the majority of the cases were only diagnosed after the onset of severe symptoms. Currently, there are more than 46 million people with AD, and this number is expected to increase to 131.5 million by 2050 worldwide1. Hence, a shift in emphasis toward identifying individuals far earlier in the disease process reflects the recognition that immediate action is required to lessen the burden of this illness.

The session also had Dr Bruce Jordan who spoke about why improving the journey to an AD diagnosis matters and presented a vision for the future. To-date, Roche’s diverse group of experts have contributed their perspectives to develop a blueprint for a patient-centred diagnostic journey for patients in the early stages of AD. Roche continues to find ways to work together across countries and stakeholders to find the right match of solutions that help optimise outcomes for AD patients and their families while making healthcare more sustainable for future challenges.

A panel discussion was then held between Dr Rachelle Doody and Professor Bruno Vellas who reflected on the twenty years of scientific experience, including obstacles, accomplishments, and lessons learned in Roche’s pathway to the advancement of AD research. The panel summarised some of the primary obstacles to be overcome in future research. These include the need for continually improving and adapting disease models, clinical trial designs, and research methods. The rate of translating newly emerging or promising results into practical applications can only be accelerated by a sustained agility and resilience commitment to solve these issues. Dr. Rachelle and Professor Bruno also discussed potential areas of current and future scientific research and development. They believe that the success of any campaign to prevent AD will truly have a significant impact on the lives of affected individuals today and tomorrow.

The fight against Alzheimer’s first starts with awareness. It is crucial to place emphasis on destigmatizing AD so that patients can realise the benefits of early diagnosis and treatment without feeling discriminated. Looking to the future, Roche is committed to further expanding the body of knowledge concerning the illness in order to resolve one of the most pressing public health issues today. Roche believes in maintaining the quality of life for individuals at risk of AD.

                                                          ***************

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalized healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche has been present in Malaysia since 1972, when the sales and distribution of products was managed by a third party distributor. Since then, Roche has established its operations to include Roche (Malaysia) Sdn. Bhd., the pharmaceutical business; Roche Diagnostics (Malaysia) Sdn. Bhd., the diagnostics business and Roche Services (Asia Pacific) Sdn. Bhd. (also referred to as Roche Services & Solutions APAC). With a total staff strength of over 1,000, Roche has grown into one of the leading healthcare companies in Malaysia that provides holistic healthcare solutions to healthcare practitioners and patients. For more information, please visit www.roche.com.my

 

 

References

1. Mat Nuri, T. H., Hong, Y. H., Ming, L. C., Mohd Joffry, S., Othman, M. F., & Neoh, C. F. (2017). Knowledge on Alzheimer's Disease among Public Hospitals and Health Clinics Pharmacists in the State of Selangor, Malaysia. Frontiers in pharmacology, 8, 739. https://doi.org/10.3389/fphar.2017.00739

Disclaimer: This session is intended for educational purposes only and not intended for any form of promotion of products.

M-MY-00000990-09-2022

Expire: 31-08-2024 unless superseded by a new version